Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline with TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN), a clinical-stage oncology company, announce that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Terns for $53.00 per share in cash for an approximate equity value of […]
